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Abstract
Aims/hypothesis The mechanism of fluid-related complica-
tions caused by thiazolidinedione derivatives is unclear. One
potential mechanism is thiazolidinedione-induced arterial
vasodilatation, which results in vascular leakage and a fall in
blood pressure, normally counterbalanced by sympathetic
activation and subsequent renal fluid retention. We hypoth-
esised that thiazolidinedione-induced vascular leakage will be
particularlyprominent in patientswithautonomic neuropathy.
Methods We conducted a randomised, double-blind,
placebo-controlled, parallel study in 40 patients with type 2
diabetes on insulin treatment recruited from a university
medical centre. The randomisation was performed by a
central office using a randomisation schedule. Both treat-
ment groups, placebo (n=21) and rosiglitazone (n=19),
were stratified for sex and level of autonomic neuropathy as
assessed by Ewing score (<2.5 or ≥2.5). We investigated
the effects of 16 weeks of treatment with rosiglitazone 4 mg
twice daily on vascular leakage (transcapillary escape rate
of albumin, TERalb), body weight, extracellular volume
and plasma volume.
Results Thirty-nine patients were included in the analysis. In
patients with high Ewing scores (n=16), rosiglitazone
increased TERalb significantly (ΔTERalb: rosiglitazone
+2.43±0.45%/h, placebo −0.11±0.15%/h, p=0.002), while
rosiglitazone had no effect in the patients with low Ewing
scores (n=23). Rosiglitazone-induced increases in TERalb
a n dE w i n gs c o r ea tb a s e l i n ew e r ec o r r e l a t e d( r=0.65,
p=0.02). There was no correlation between Ewing score and
rosiglitazone-induced changes in fluid variables. One subject
was withdrawn from the study because of atrial fibrillation.
Conclusions/interpretation Rosiglitazone may increase
vascular leakage in insulin-treated patients with type 2
diabetes with autonomic neuropathy. Autonomic neuro-
pathy did not exaggerate rosiglitazone-induced fluid
retention. Therefore, autonomic neuropathy should be
considered as a risk factor for thiazolidinedione-induced
oedema, not for thiazolidinedione-induced fluid retention.
Trial registration ClinicalTrials.gov NCT00422955
Funding GlaxoSmithKline
Keywords Autonomic neuropathy.Clinical science.
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Thiazolidinedione derivatives are used in the treatment
of type 2 diabetes as they improve insulin sensitivity
and reduce blood glucose concentration [1, 2]. Besides
their effect on glycaemia, thiazolidinediones appear to
have favourable effects on plasma lipids, blood pressure,
fibrinolysis and inflammation, which might offer addition-
al beneficial effects beyond glucose lowering with respect
to the prevention of cardiovascular disease [3]. There is
intense scientific dispute about whether thiazolidine-
diones, particularly rosiglitazone, protect against cardio-
vascular disease or may even increase the risk of
ischaemic cardiovascular events [4–7]. Part of the benefi-
cial effects of thiazolidinediones may be outbalanced by
side effects, especially fluid retention. For example, the
PROspective pioglitAzone Clinical Trial In macroVascular
Events (PROActive) study showed a trend towards a
reduced risk of cardiovascular events with pioglitazone
compared with placebo in persons with type 2 diabetes,
but this benefit was largely offset by fluid-related adverse
events, oedema formation and heart failure [8]. The
mechanism of fluid retention is unclear [9], but unravel-
ling the mechanism would identify risk factors for the use
of thiazolidinediones and enable the prescription of
thiazolidinedione therapy only for patients with a favour-
able benefit/risk ratio.
Based on the demonstration in preclinical studies that
thiazolidinediones stimulate epithelial sodium channels in the
renal collecting duct [10, 11], it has been suggested that
thiazolidinedione-related fluid retention in humans is caused
by primary renal mechanisms, although a recent preclinical
study showed opposing results [12] and human experimental
data are lacking. Primary renal sodium retention would also
increase blood pressure, which is at odds with the observed
blood pressure lowering effect of thiazolidinediones [13, 14].
As the initiating key mechanism, thiazolidinedione-induced
arterial vasodilatation [9] explains both blood pressure
reduction and fluid retention. The local microvascular
consequence of arterial vasodilatation is increased hydrostat-
ic capillary pressure with more vascular leakage and the
formation of interstitial fluid. The systemic consequence is
reduction in peripheral vascular resistance [15] and blood
pressure, which is the driving force for secondary renal
sodium retention. Meanwhile, the sympathetic nervous
system counteracts the vasodilator effect [16], reducing the
increment in vascular leakage and preventing an exaggerated
fall in blood pressure and the consecutive increment in
sodium retention. Sympathetic activation also directly
stimulates renin production, which induces sodium retention.
Therefore, the net effect of the increased sympathetic tone on
renal sodium retention is unclear (Fig. 1).
Patients with autonomic failure are not able to counter-
balance haemodynamic changes effectively, which will
result in an unopposed change in capillary hydrostatic
force. Indeed, some case reports suggest that the haemody-
namic effects of insulin are exaggerated in persons with
autonomic neuropathy [17, 18], while blockade of the
autonomic nervous system may increase insulin-induced
vascular leakage [19].
Epidemiological data support this mechanistic line of
reasoning. It has been reported that the incidence of oedema
Hydrostatic Vascular
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+
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+
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_
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Fig. 1 Schematic representation of the hypothesis. The local
consequence of rosiglitazone-induced vasodilatation will be increased
hydrostatic pressure leading to an elevation in capillary filtration
(vascular leakage), which predisposes to oedema formation (top). An
intact sympathetic nervous system counteracts the vasodilator effect,
which will prevent increased vascular leakage. The systemic conse-
quence of vasodilatation is reduction of blood pressure (bottom),
leading to renin production and sodium retention. On the one hand, an
intact sympathetic nervous system prevents reduction in blood
pressure immediately; on the other hand, sympathetic activation
directly stimulates renin production; the result is diminished and
elevated sodium retention respectively. RAAS, renin–angiotensin–
aldosterone system
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insulin [9]. This may be due to a combined effect of
thiazolidinediones and insulin or to complications accom-
panying longstanding diabetes [9]. In a previous study in
insulin-resistant people without diabetes, we found no
evidence for adverse vascular effects of the combined use
of rosiglitazone and insulin [20], suggesting that it is not
insulin itself but probably complications associated with
longstanding diabetes that render patients prone to oedema
formation. Autonomic neuropathy is a typical complication
of longstanding diabetes [21, 22].
In the present study in insulin-treated patients with type 2
diabetes, we investigated whether thiazolidinedione-
induced microvascular leakage is more pronounced in
patients with autonomic neuropathy. We also investigated
whether autonomic neuropathy affects thiazolidinedione-
induced fluid retention.
Methods
The study population consisted of 40 participants with
type 2 diabetes, who had received insulin treatment for at
least 6 months. Further inclusion criteria were age between
30 and 75 years, body mass index <40 kg/m
2 and fasting
plasma glucose between 7.0 and 15 mmol/l. Participants
were not eligible for inclusion if HbA1c was higher than
12%, if they used over 200 U insulin a day, if they used oral
hypoglycaemic drugs other than metformin, if they used
any investigational drug or had used a peroxisome
proliferator activated-receptor γ (PPARγ) agonist within
4 months before the start of the study, or had a significant
history of hypersensitivity to a peroxisome proliferator
activated receptor γ (PPARγ) agonist. Additional exclusion
criteria were blood pressure exceeding 160/90 mmHg,
symptomatic postural hypotension, diuretic therapy for
oedema, unstable or severe angina or congestive heart
failure, any cardiovascular event in the last 6 months before
entry to the study, the presence of clinically significant
hepatic disease or anaemia, calculated creatinine clearance
below 40 ml/min, pregnancy, lactation, women of child-
bearing potential without appropriate contraception, and
alcohol or drug abuse. To overcome confounding in the
interpretation of the Ewing score, all participants using
alpha or beta blockers were excluded. Study participants
were either selected by advertisement or invited by their
own physician at the outpatient clinic of the Radboud
University Nijmegen Medical Centre or Rijnstate or
Catharina Hospital. The participants received a payment
and gave written informed consent. The study was
approved by the hospital ethics committee, registered at
clinical trials.gov and performed according to Good
Clinical Practice guidelines.
Procedure
This was a randomised, placebo-controlled, double-blind,
single-centre, parallel study with 4 weeks of single-blind
run-in. At screening, the Ewing score was determined to
quantify autonomic neuropathy [22]. In short, continuous
finger arterial pressure and cardiac cycle duration (R-R
interval) were recorded on a PC-based data acquisition
system during five standardised tests. Heart rate responses
to the Valsalva manoeuvre (longest R-R interval after the
manoeuvre divided by the shortest R-R interval during the
manoeuvre; normal values are >1.21), to deep breathing
(maximum–minimum heart rate during a breathing cycle;
normal values ≥15 bpm) and to standing up (longest R-R
interval [±30th beat] divided by the shortest R-R interval
[±15th beat]; normal values are ≥1.04) were measured to
determine parasympathetic function, and the blood pressure
responses to standing up (fall in systolic blood pressure
[SBP]; normal values ≤10 mmHg) and to sustained hand
grip (increase in diastolic blood pressure [DBP]; normal
values ≥16 mmHg) were determined as a measure of
sympathetic function. Each result was compared with the
normal response and scored as normal, borderline or
abnormal, which were allocated 0, 1/2 and 1 point
respectively. The total score ranges from 0 to 5. The
participants were divided into two groups with Ewing score
either ≥2.5 or <2.5. Throughout this article the groups are
referred to as having high versus low Ewing scores or
established autonomic neuropathy versus mild or no
autonomic neuropathy. Four weeks after screening (week
−4), eligible participants were randomised to either rosigli-
tazone 4 mg twice daily or placebo for 16 weeks in a 1:1
ratio (week 0) and balanced for the two Ewing score groups
within 40–60% boundaries. The participants were assigned
to study treatment in accordance with the randomisation
schedule via the automatic GlaxoSmithKline Registration
and Medication Ordering System, which could be reached
by phone. At week 0 and week 16, primary endpoint
experiments were performed. Vascular leakage was
assessed as the transcapillary escape rate of albumin
(TERalb). During all visits, including the control visits in
weeks 4, 8 and 12, adverse events and pill compliance were
recorded and blood glucose lowering pharmacotherapy was
adjusted. If a participant repeatedly had measurements
below 4 mmol/l, the metformin dose was decreased, as it
was our intention to keep the insulin dose as constant as
possible during the study. In addition, we performed a
physical examination, measured body composition using
bioimpedance and foot volume, and chemical, haematolog-
ical, and glycaemic safety profiles were determined. There
was a final follow-up visit in week 18. Participants were
strictly advised to maintain their diet and not to change
lifestyle throughout the study.
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Each participant attended the hospital after an overnight fast
without taking insulin or oral blood glucose lowering pharma-
cotherapy in the morning. The procedure started at 08:00 hours
in a quiet, temperature-controlled room (23–24°C) with the
participant in supine position. A venous catheter (Venflon,
20 gauge, 32 mm; Becton Dickinson, Sandy, UT, USA) was
inserted for the infusion of either insulin or glucose to keep the
glucose level between 5 and 12 mmol/l. During the experiment,
plasma glucose was measured every 20 min (Glucocard
Memory 2; Menarini, Florence, Italy). The participant was
asked to inject his or her normal morning insulin dose. Then, a
20 gauge catheter (Angiocath; Becton Dickinson) was inserted
into the left brachial artery under local anaesthesia (0.3–0.4 ml
lidocaine HCl 20 mg/ml; Braun, Melsungen, Germany),
connected to an arterial pressure monitoring line and kept
patent with heparin in saline 0.9% (2 U/ml, 3 ml/h; NaCl 0.9%,
Baxter, Utrecht, the Netherlands; heparin, Leo Pharma,
Ballerup, Denmark). This catheter was used for blood
sampling and blood pressure measurement. After 30 min of
supine rest, blood was drawn for hormone analysis (atrial
natriuretic peptide [ANP], aldosterone and renin) and for
baseline TERalb measurement. An additional venous needle
(Valu-Set, 0.6×20 mm; Becton Dickinson) was inserted and
7.4×10
4–14.8×10
4 Bq
125I-labelled albumin (Schering Neder-
land, Weesp, the Netherlands) was given as an i.v. bolus
injection at 0 min. Over the next 60 min, seven plasma
samples were collected from the arterial line for radioactivity
measurements.
Bioimpedance
During all visits, total body water (TBW) and extracellular
volume (ECV) were assessed using an Akern 2000 bioelec-
trical impedance analyser [23] (Akern, Florence, Italy).
Foot volume
Foot volume was assessed by the water displacement
method using an electronic balance (coefficient of variation,
0.30%) [24]. The balance recorded the force necessary for a
standardised immersion of the foot, which depends solely
on the volume of the foot (Archimedes’ principle).
Analytical methods
Plasma ANP was analysed by radioimmunoassay after
cartridge extraction (Phoenix Pharmaceuticals, Burlingame,
CA, USA). Plasma renin was determined with a two-site
immunochemiluminometric assay (Diagnostic System Lab-
oratories, Webster, TX, USA). Plasma aldosterone was
analysed using antibody-coated tubes and competing radio-
labelled aldosterone (Diagnostic Products, Los Angeles,
CA, USA).
Calculations
For each TERalb test the measured radioactivity was
plotted over time. An extinction curve was drawn assuming
first-order kinetics. Slope and the extrapolated peak plasma
concentration at t=0 were calculated using Microsoft Excel.
Plasma volume and TERalb were calculated using the
following formulas [20, 25]:
Plasma volume ðmlÞ=1:73 m2 ¼
cpm injected=cpmt ¼ 0=ml ðÞ =surface m2 ðÞ =1:73 m2
TERalb ¼ 1   e3600 slope 
  100 %=h ðÞ :
To ensure reliable results, calculated plasma volume and
TERalb were excluded from primary endpoint analysis when
the correlation coefficient between the extinction curve and
the actual measured time points was below 80%. Creatinine
clearance was calculated with the Cockcroft formula [26].
Statistical analysis
The groups were balanced for sex and Ewing score. For
variables measured at baseline and in week 16, only
participants with paired observations were included. For
variables with additional assessments, intention-to-treat pop-
ulations both with and without last observation carried
forward were analysed. The difference between the two
treatment groups in either the total population or in one of the
Ewing score subgroups was estimated by analysis of
covariance with terms for treatment, sex, baseline measure-
ment and, if applicable, Ewing score. Similarly, the difference
in treatment effect between participants from different Ewing
score subgroups was estimated by analysis of covariance with
termsforsex,baselineandEwingscore.Fortheassessmentof
various relationships, the partial correlation coefficient was
estimated with adjustment for sex. All significance tests were
two-sided and the overall type I error was 5%. Descriptive
statistics are presented as mean and standard deviation or as
percentage. Treatment effects are presented as mean with
standard error. All statistical analyses were performed using
the SAS software package (SAS Institute, Cary, NC, USA).
Results
A total of 40 participants were included in the study; 21
participants received placebo and 19 rosiglitazone (Fig. 2).
One participant in the rosiglitazone group was withdrawn
after 8 weeks because of atrial fibrillation and heart failure.
Thirteen participants in the rosiglitazone-treated group and
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reliability criteria for TERalb measurements and were
included in the analysis of the primary endpoint.
There were no clinically significant differences in
baseline characteristics between the treatment groups in
the total population, nor were there differences between the
randomised subgroups, except for Ewing score (Table 1).
Sixteen participants were classified with Ewing scores ≥2.5.
Drug compliance was excellent. The 39 participants who
finished the study reported only mild side effects. Oedema
was more prevalent in the rosiglitazone group than in the
placebo group (63% vs 24%, p<0.05), but always mild, and
not different between participants with high and low Ewing
scores.
Total population
In this section the model-adjusted treatment effects of rosigli-
tazone and placebo are given. A summary of the raw endpoint
data at baseline and after treatment for the total population is
provided in Electronic supplementary material (ESM) Table 1.
Effect of rosiglitazone on glycaemic control Rosiglitazone
improved glycaemic control (HbA1c; rosiglitazone −0.67±
0.15%, placebo −0.24±0.14%, p<0.05) despite a sig-
nificant reduction in the daily insulin dose (rosiglitazone
−11±2 U/day, placebo +2±2 U/day, p<0.0001) and a slight
decrease in background metformin treatment.
Effect of rosiglitazone on vascular leakage and diastolic
blood pressure There was a trend for rosiglitazone to
increase vascular leakage (TERalb; rosiglitazone +1.38±
0.46%/h, placebo +0.29±0.40%/h, p=0.09). Rosiglitazone
decreased the intra-arterially measured DBP (rosiglitazone
−2.3±1.1 mmHg, placebo +1.4±1.1 mmHg, p=0.02).
Effect of rosiglitazone on fluid variables and vascular hormones
During rosiglitazone treatment, plasma volume (rosiglitazone
220±71 ml/1.73 m
2,p l a c e b o−21±64 ml/1.73 m
2, p=0.02)
and body weight (rosiglitazone +2.4±0.5 kg, placebo
+0.5±0.4 kg, p=0.004) increased, while haematocrit
decreased (rosiglitazone −0.024±0.005, placebo −0.005±
0.005, p=0.007). Rosiglitazone did not increase ECV
(rosiglitazone +0.8±0.2 l, placebo +0.4±0.2 l, p=0.18) and
TBW (rosiglitazone+1.0±0.3 l,placebo +0.4±0.3 l,p=0.12),
and had no effect on foot volume. In addition, rosiglitazone
increased plasma ANP (rosiglitazone +64±20 ng/l, placebo
−1±18 ng/l, p=0.02) but did not influence plasma renin and
aldosterone levels.
Low and high Ewing score subgroups
A summary of raw endpoint data and model-adjusted
treatment effects of rosiglitazone and placebo within these
Ewing score subgroups is provided in Table 2.
Effect of rosiglitazone on glycaemic control The changes
in glycaemic control and insulin requirements did not differ
between the two Ewing score subgroups.
Effectofrosiglitazoneonvascularleakageandbloodpressure
In the subgroup of patients with high Ewing scores,
rosiglitazone significantly increased TERalb (rosiglitazone
2.43±0.45%/h, placebo −0.11±0.42%/h, p=0.002), while
rosiglitazone had no effect in the subgroup of patients with
low Ewing scores (rosiglitazone −0.44±0.72%/h, placebo
1.04±0.56%/h, not significant; Fig. 3a). As a result,
rosiglitazone significantly increased TERalb in patients
with high Ewing scores compared with those with low
Ewing scores (high Ewing score 2.54±0.49%/h, low Ewing
score 0.58±0.53%/h, p=0.03).
In the rosiglitazone-treated patients the reduction in intra-
arterial DBP tended to be more pronounced in participants
with high Ewing scores (rosiglitazone −3.1±1.2 mmHg,
Excluded (n=21): 
Recruitment
()
￿ BP >160/90 mmHg (n=5)       
￿ FPG <7 mmol/l (n=3) ￿     (
Di b t t 1 ( 2) ￿ a etes type 1 (n=2)
￿ Hepatic disease (n=2) Assessed for eligibility 
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￿No autonomic neuropathy,  Randomised  py ,
while for balancing   purposes 
hi d ( )
(n=40)
neuropathy was required  (n=5)
Rosiglitazone (n=19) Placebo (n=21) Rosiglitazone (n=19)   
Low Ewing score=11 
Placebo (n=21)      
Low Ewing score=13  g
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g
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Fig. 2 Enrolment of study participants, distribution among subgroups
and flow of participants through the study.
aTo ensure reliable results,
calculated transcapillary escape rates of albumin (TERalb) with
correlation coefficients below 80% between the extinction curve and
the actual measured time points were excluded from this analysis.
FPG, fasting plasma glucose
1860 Diabetologia (2010) 53:1856–1866placebo +1.2±1.3 mmHg, p=0.03) than in those with low
Ewing scores (rosiglitazone −2.2±1.7 mmHg, placebo
+1.6±1.5 mmHg, p=0.11).
Effect of rosiglitazone on fluid variables and vascular
hormones In the subgroup of patients with a high Ewing
score, rosiglitazone did not increase fluid variables and
decrease haematocrit significantly, while in the patients
with low Ewing scores rosiglitazone seemed to increase
plasma volume, TBW and body weight, and did decrease
haematocrit (Table 2). The difference in effect of rosiglita-
zone over placebo in both subgroups was partly driven by
the different response to placebo in these subgroups.
Correlations
Baseline Ewing score and change in vascular leakage or
fluid variables In patients randomised to rosiglitazone, the
increase in TERalb was highly correlated with the Ewing
score atbaseline(r=0.65,p=0.02; Fig. 3b), while the change
in TERalb during placebo treatment was not (r=0.12,
p=0.66). The correlation between the increase in TERalb
during rosiglitazone treatment and baseline Ewing score was
even more robust after inclusion of all the TERalb results
(r=0.72,p=0.002), showing that the exclusion of qualitative
weak TERalb measurements neither biased nor caused the
relationship. As participants with a high Ewing score had a
significantly higher BMI than those with a low Ewing score,
we also evaluated the correlation between the change in
TERalb during rosiglitazone treatment and baseline BMI
(r=0.11) but this correlation was not significant. Further-
more, the changes in intra-arterial DBP while taking
rosiglitazone were not significantly correlated with baseline
Ewing score (r=−0.28). In addition, the changes in body
weight, haematocrit, plasma volume, TBW and ECV during
rosiglitazone treatment were not correlated with the Ewing
score at baseline.
Correlation between change in vascular leakage and change
in diastolic blood pressure or fluid variables As expected
from the vascular hypothesis, changes in DBP in
patients receiving rosiglitazone were strongly inversely
correlated to changes in vascular leakage in participants
with high Ewing scores (r=−0.96, p=0.002, Fig. 4a),
indicating that participants with a large decrease in blood
pressure had a large increase in vascular leakage. This
Table 1 Baseline characteristics
Variable Total population Ewing score <2.5 Ewing score ≥2.5
Rosiglitazone
(n=19)
Placebo
(n=21)
Ewing score
<2.5 (n=24)
Ewing
score ≥2.5
(n=16)
Rosiglitazone
(n=11)
Placebo
(n=13)
Rosiglitazone
(n=8)
Placebo
(n=8)
Age (years) 58±8 59±10 59±8 58±10 58±9 60±8 59±6 57±13
Male (%) 58 57 63 50 64 62 50 50
BMI (kg/m
2) 29±4 29±6 28±4 31±6
d 28±4 27±5 30±3 32±8
Waist circumference
(cm)
101±10 101±17 97±13 105±14 98±10 97±15 104±9 107±19
SBP (mmHg) 132±15 132±15 132±12 132±18 131±13 133±13 133±19 131±19
DBP (mmHg) 80±6 80±7 80±6 80±7 80±4 80±8 79±8 80±6
Heart rate (1/min) 73±10 75±11 73±12 76±7 70±10 75±13 77±7 75±8
Calculated creatinine
clearance (ml/min)
89±16 85±30 86±19 88±32 92±15 81±21 84±17 92±42
Urinary albumin/creatinine
ratio (mg/mmol
creatinine)
0.9±1.4 3.9±13.3 0.9±1.3 5.1±15.5 1.0±1.9 0.8±0.8 0.9±0.5 10.7±23.5
Duration of diabetes
(years)
12.8±7.8 14.1±5.7 13.1±6.9 14.0±6.5 11.2±8.0 14.6±5.8 14.9±7.4 13.1±5.9
HbA1c (%) 7.7±1.4 8.1±1.1 7.7±1.2 8.3±1.3 7.5±1.3 7.8±1.0 8.0±1.4 8.6±1.1
Insulin dose (U/day) 60±40 64±33 58±28 69±45 57±24 58±32 64±56 74±34
Metformin (%) 32 43 29 50 18 38 50 50
Ewing score 2.1±1.3 1.7±0.9 1.2±0.6 3.0±0.8
c 1.2±0.6 1.1±0.6 3.3±0.9
a 2.7±0.5
b
Data are mean ± SD
ap<0.05 versus rosiglitazone, Ewing score <2.5
bp<0.05 versus placebo, Ewing score <2.5
cp<0.001 versus Ewing score <2.5
dp<0.05 versus Ewing score <2.5
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1862 Diabetologia (2010) 53:1856–1866correlation was not significant in participants with low
Ewing scores.
In patients taking rosiglitazone, the change in vascular
leakage was inversely correlated with the change in
TBW (r=−0.76, p=0.004; Fig. 4b)a n dE C V( r=−0.65,
p=0.02).
Discussion
There are two main clinically relevant findings in the
present study. First, in the presence of autonomic neurop-
athy, rosiglitazone induced vascular leakage in insulin-
treated patients with type 2 diabetes. Second, neither
autonomic neuropathy nor the increase in vascular leakage
in itself led to increased fluid retention. Together, these
findings suggest that, in established autonomic neuropathy,
thiazolidinediones will lead to exaggerated vascular leakage
but not necessarily to more pronounced fluid retention.
Nevertheless, increased vascular leak will render these
patients more susceptible to oedema formation.
We postulate that thiazolidinediones have a vasodilator
action, which subsequently promotes vascular leakage into
interstitial tissues. In the present study, vascular leakage
indeed tended to increase during treatment with rosiglita-
zone, although the effect was not statistically significant.
Predefined subgroup analyses, however, showed a clear
increase in vascular leak following treatment with rosigli-
tazone in participants with established autonomic neurop-
athy but not in participants with absent or mild autonomic
neuropathy. This was confirmed by the positive correlation
between Ewing score and change in TERalb. The findings
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(continuous) and change in TERalb (individual raw data, therefore
not model-adjusted) during treatment with rosiglitazone
Diabetologia (2010) 53:1856–1866 1863suggest that autonomic nerve damage in diabetic people
prevents sympathetic nerve stimulation from counteracting
the vasodilator effects of rosiglitazone. This concept
(Fig. 1) is supported by the strong inverse correlation
between changes in diastole. All in all, the findings fit with
the concept that defective counter-regulation of haemody-
namic changes caused by autonomic neuropathy exagger-
ates vascular leakage induced by thiazolidinediones. In
persons with no or mild autonomic neuropathy, rosiglita-
zone did not increase vascular leakage, which is in
accordance with previous human [20] and preclinical [27]
findings.
The notion that autonomic neuropathy results in a
defective counterbalance towards rosiglitazone-induced
vasodilatation and subsequent vascular leakage has two
consequences. First, people who are prone to vascular
leakage should be protected against excessive plasma
volume expansion, because excess fluid would leak out of
the plasma compartment. Indeed, we did not observe either
a disproportional increase in plasma volume or a decrease
in haematocrit during rosiglitazone treatment in participants
with established autonomic neuropathy. Second, excessive
leakage should result in increases in TBW and ECV. This,
however, was not observed in the present study: if
anything, changes in TBW and ECV were smaller in the
established autonomic neuropathy group. This apparent
discrepancy can be explained by the complicated relation
between sympathetic counter-regulation and renal sodium
retention. The sympathetic nervous system responds to
systemic hypoperfusion, both by direct renal sodium
retention and by activation of the renin–angiotensin–
aldosterone system [28]. In fact, after drug-induced vaso-
dilatation an intact sympathetic nervous system protects the
body against local vascular leakage by reflex vasoconstric-
tion and against systemic hypoperfusion by sodium
retention. Consequently, a defective sympathetic nervous
system will lead to vascular leakage without much sodium
retention (Fig. 1). In both situations vascular leakage should
be inversely correlated with and ECV and TBW, and this
indeed is in complete agreement with our findings
(Fig. 4b). The clinical implication of our observations is
that insulin-treated patients with diabetic autonomic neu-
ropathy may be partly protected from fluid overload by
sodium retention induced by thiazolidinediones, but on the
other hand will be more prone to vascular oedema, as a
consequence of microvascular imbalance.
The prevalence of oedema was much higher in our study
than in another study in insulin-treated patients performed
by Raskin et al. [13], both during placebo treatment
(present study 24%, Raskin et al. 4%) and during
rosiglitazone treatment (present study 64%, Raskin et al.
17%). A potential explanation of this difference is that we
were more focused on the development of oedema because
oedema was a main outcome in our study. Another
explanation could be the high prevalence of autonomic
neuropathy in our population, although there was no
correlation between Ewing score and the clinical finding
of oedema. The reason we found differences in vascular
leakage but not in oedema formation between the auto-
nomic neuropathy subgroups during rosiglitazone treatment
seems to be the absence of a reliable clinical test to
quantitatively assess changes in total body interstitial fluid
(oedema) in a chronic setting. Vascular leakage was
measured as the mean of total body capillary leakage while
oedema was measured only locally in the foot. For instance,
changes in visceral vascular leakage will not influence foot
volume.
In the present study, the glycaemic effect of rosiglitazone
was moderate (a decrease in HbA1c of 0.42%) and
seemingly less than expected. For example, Raskin et al.
[13] reported a treatment effect of −1.3%. This difference
may be explained by the shorter treatment period, the lower
baseline HbA1c, the reduction in insulin dose, the slight
decrease in background metformin use during rosiglitazone,
and the marked glycaemic improvements in the placebo
group.
The participant who was withdrawn from this study with
atrial fibrillation had used beta blocker therapy for
subjective palpitations in the past. She discontinued this
therapy 1 month before entry into the study. Atrial
fibrillation and oedema resolved quickly after re-
institution of beta blocker therapy and discontinuation of
rosiglitazone. Despite correction of the rhythm, the partici-
pant was withdrawn as beta blocker therapy would have
been a confounder in the final analyses.
To assess the degree of autonomic neuropathy, different
methods, each with important limitations, are being used.
We used the Ewing score, as it is well validated, widely
accepted, non-invasive and suitable for screening. A
disadvantage of the Ewing score is that there is no
international consensus on how to adjust the tests for
ageing. We have our own age-adjusted reference tables but
these have not been published. Therefore, in this study we
used the internationally accepted Ewing tests without age
adjustment. We did perform a post hoc analysis after
adjusting the Ewing score for age, but this did not result in
any change in study outcome (data not shown).
We also measured baseline arterial plasma noradrenaline
(norepinephrine) and adrenaline (epinephrine) and calculat-
ed the noradrenaline appearance rate (data not shown),
which tended to be lower in the group with established
autonomic neuropathy, suggesting that the higher Ewing
score did indeed reflect autonomic neuropathy.
While sympathetic dysfunction is most relevant for
our hypothesis, the Ewing score is based on parasym-
pathetic as well as sympathetic tests [22]. In most
1864 Diabetologia (2010) 53:1856–1866patients the initial manifestation of autonomic disease is
an abnormal response to the parasympathetic tests,
followed by abnormal sympathetic tests in more severe
autonomic neuropathy [21]. The increased frequency of
abnormalities found with the parasympathetic tests may
reflect both earlier involvement of parasympathetic dam-
age and better sensitivity of the parasympathetic tests. To
maximise the separation of participants with and without
sympathetic neuropathy, we divided our population on the
basis of the Ewing score into two categories with a cut-off
value of 2.5, rather than the original four categories
described by Ewing (normal, early, definite and severe).
Indeed, more participants in the ≥2.5 group had abnor-
malities in the sympathetic nerve tests than in the <2.5
group (data not shown). In line with the concept of
sympathetic counterbalance, rosiglitazone increased vas-
cular leakage in participants in whom a high Ewing score
was combined with sympathetic disturbances in a post hoc
analysis. On the contrary, rosiglitazone did not influence
vascular leakage in participants with a low Ewing score
and no sympathetic disturbances.
In conclusion, in insulin-treated type 2 diabetes patients
who have autonomic neuropathy, thiazolidinediones in-
crease vascular leakage and render the patient susceptible to
the development of oedema. Autonomic neuropathy in
itself does not exaggerate thiazolidinedione-induced fluid
retention. Therefore, autonomic neuropathy should be
considered as a risk factor for thiazolidinedione-induced
oedema, not for fluid retention.
Acknowledgements This study was supported by GlaxoSmithKline.
We thank the Department of Nephrology, Radboud Univeristy
Nijmegen Medical Centre, for the use of the research room and the
foot volume equipment. We thank H. de Boer and B. Bravenboer,
diabetologists at Rijnstate and Catherine Hospital, respectively, for
their help in recruiting study participants.
Duality of interest M. W. Stewart is a full-time employee of
GlaxoSmithKline. C. J. Tack and A. J. Rennings have participated in
advisory panels for GlaxoSmithKline.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med
351:1106–1118
2. Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability
of rosiglitazone, metformin, or glyburide monotherapy. N Engl J
Med 355:2427–2443
3. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca
VA (2001) Nonhypoglycemic effects of thiazolidinediones. Ann
Intern Med 134:61–71
4. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of
myocardial infarction and death from cardiovascular causes.
N Engl J Med 356:2457–2471
5. Home PD, Pocock SJ, Beck-Nielsen H et al (2007) Rosiglitazone
evaluated for cardiovascular outcomes—an interim analysis.
N Engl J Med 357:28–38
6. GersteinHC,MillerME,ByingtonRPetal(2008)Effectsofintensive
glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559
7. Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone
evaluated for cardiovascular outcomes in oral agent combination
therapy for type 2 diabetes (RECORD): a multicentre, rando-
mised, open-label trial. Lancet 373:2125–2135
8. Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary
prevention of macrovascular events in patients with type 2
diabetes in the PROactive Study (PROspective pioglitAzone
Clinical Trial In macroVascular Events): a randomised controlled
trial. Lancet 366:1279–1289
9. Nesto RW, Bell D, Bonow RO et al (2003) Thiazolidinedione use,
fluid retention, and congestive heart failure: a consensus statement
from the American Heart Association and American Diabetes
Association. October 7, 2003. Circulation 108:2941–2948
10. Guan Y, Hao C, Cha DR et al (2005) Thiazolidinediones expand
body fluid volume through PPARgamma stimulation of ENaC-
mediated renal salt absorption. Nat Med 11:861–866
11. Hong G, Lockhart A, Davis B et al (2003) PPARgamma activation
enhances cell surface ENaCalpha via up-regulation of SGK1 in
human collecting duct cells. FASEB J 17:1966–1968
12. Vallon V, Hummler E, Rieg T et al (2009) Thiazolidinedione-
induced fluid retention is independent of collecting duct alphaE-
NaC activity. J Am Soc Nephrol 20:721–729
13. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J
(2001) A randomized trial of rosiglitazone therapy in patients with
inadequately controlled insulin-treated type 2 diabetes. Diab Care
24:1226–1232
14. Shimkets RA, Warnock DG, Bositis CM et al (1994) Liddle’s
syndrome: heritable human hypertension caused by mutations in
the beta subunit of the epithelial sodium channel. Cell 79:407–414
15. Shargorodsky M, Wainstein J, Gavish D, Leibovitz E, Matas Z,
Zimlichman R (2003) Treatment with rosiglitazone reduces
hyperinsulinemia and improves arterial elasticity in patients with
type 2 diabetes mellitus. Am J Hypertens 16:617–622
16. Lindqvist M, Kahan T, Melcher A, Hjemdahl P (1994) Acute and
chronic calcium antagonist treatment elevates sympathetic activity
in primary hypertension. Hypertension 24:287–296
17. Page MM, Watkins PJ (1976) Provocation of postural hypotension
by insulin in diabetic autonomic neuropathy. Diabetes 25:90–95
18. Seyer-Hansen K (1977) Postprandial hypotension. Br Med J 2:1262
19. Hilsted J, Frandsen H, Christensen NJ, Nielsen SL (1991) Plasma
volume changes during hypoglycaemia: the effect of autonomic
blockade. Eur J Clin Invest 21:22–26
20. Rennings AJ, Smits P, Stewart MW, Tack CJ (2006) Fluid
retention and vascular effects of rosiglitazone in obese, insulin-
resistant, nondiabetic subjects. Diab Care 29:581–587
21. Vinik AI, Maser RE, Mitchell BD, Freeman R (2003) Diabetic
autonomic neuropathy. Diab Care 26:1553–1579
22. Ewing DJ, Martyn CN, Young RJ, Clarke BF (1985) The value of
cardiovascular autonomic function tests: 10 years experience in
diabetes. Diab Care 8:491–498
23. Lukaski HC (1987) Methods for the assessment of human body
composition: traditional and new. Am J Clin Nutr 46:537–556
24. van Hamersvelt HW, Kloke HJ, de Jong DJ, Koene RA,
Huysmans FT (1996) Oedema formation with the vasodilators
nifedipine and diazoxide: direct local effect or sodium retention?
J Hypertens 14:1041–1045
25. Parving HH, Gyntelberg F (1973) Albumin transcapillary escape
rate and plasma volume during long-term beta-adrenergic
Diabetologia (2010) 53:1856–1866 1865blockade in essential hypertension. Scand J Clin Lab Invest
32:105–110
26. Cockcroft DW, Gault MH (1976) Prediction of creatinine
clearance from serum creatinine. Nephron 16:31–41
27. Cosson E, Cohen-Boulakia F, Tarhzaoui K et al (2009)
Capillary endothelial but not lymphatic function is restored
under rosiglitazone in Zucker diabetic fatty rats. Microvasc
Res 77:220–225
28. Osborn JL, Holdaas H, Thames MD, DiBona GF (1983) Renal
adrenoceptor mediation of antinatriuretic and renin secretion
responses to low frequency renal nerve stimulation in the dog.
Circ Res 53:298–305
1866 Diabetologia (2010) 53:1856–1866